ReviewCancer treatment reviews2020
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.
Review in Cancer treatment reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 115 citations in OpenAlex.
- Pulmonary sarcomatoid carcinoma in the anterior mediastinum mimicking thymic carcinoma with rapid widespread metastases: A case report.Medicine · 2026Article
- Diagnostic Value of Next-Generation Sequencing (NGS) and Microarray in Characterizing Tumor Origin: A Challenging and Educational Case.The American journal of case reports · 2026Article
- Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives.Journal of hematology & oncology · 2026Review
- Targeted therapies in lung cancer: personalizing treatment across the age spectrum.Frontiers in oncology · 2026Review
- Observational
- Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction.NPJ precision oncology · 2025Article
- Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond.Frontiers in pharmacology · 2025Review
- Review
- A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases.International journal of molecular sciences · 2024Review
- Multisequence MRI-based radiomics signature as potential biomarkers for differentiating KRAS mutations in non-small cell lung cancer with brain metastases.European journal of radiology open · 2024Article
- Targeting KRASDrugs · 2024Review
- Oncogenic alterations in advanced NSCLC: a molecular super-highway.Biomarker research · 2024Review
- Resistance to KRAS inhibition in advanced non-small cell lung cancer.Frontiers in oncology · 2024Review
- Nonsmall-cell lung cancer treatment: current status of drug repurposing and nanoparticle-based drug delivery systems.Turkish journal of biology = Turk biyoloji dergisi · 2024Article
- Invasive Diagnostic Procedures from Bronchoscopy to Surgical Biopsy-Optimization of Non-Small Cell Lung Cancer Samples for Molecular Testing.Medicina (Kaunas, Lithuania) · 2023Review
- Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer.Current oncology reports · 2023Review
- Prognostic Implication ofJTO clinical and research reports · 2023Article
- Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma.ACS omega · 2023Review
- Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.Current oncology (Toronto, Ont.) · 2023Article
- Frizzled-7-targeting antibody (SHH002-hu1) potently suppresses non-small-cell lung cancer via Wnt/β-catenin signaling.Cancer science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
Cancers of nearly all lineages harbor alterations that deregulate mitogen-activated protein kinase signaling, a crucial signaling pathway for tumor formation and maintenance. Of these, KRAS mutations are the most frequent gain-of-function alterations found in patients with cancer. In particular they represents the most common molecular alteration detected in non-small cell lung cancer (NSCLC) accounting for up to 25% of all oncogenic mutations. They were identified decades ago and prior efforts to target these proteins have been unsuccessful. KRAS mutation profiles (i.e. frequency of specific codon substitutions) in smokers and never-smokers are distinct and not all KRAS alterations are driver mutations. KRAS has evolved from a mutation with possible predictive value to a therapeutic target with great promise. Here, we will discuss the biology of KRAS in lung cancer and its clinical implications in oncology today and in the foreseeable future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.